ICU Medical, Inc.
ICUI Healthcare Medical Instruments & Supplies
ICU Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, down 6.33% from fiscal 2024.
- Revenue
- +4.37%
- EPS
- +864.3%
- Free cash flow
- +292.2%
- Total debt
- −12.3%
Quarter to September 2026, against a year earlier
Follow ICUI
Alert me
ICU Medical, Inc. (ICUI) EV/EBITDA
As of 5 November 2026, ICU Medical, Inc. (ICUI) trades at a EV/EBITDA of 16.0×. Over the past ten years it has ranged from 11.2× (February 2016) to 430× (December 2017); the current reading is higher than 20% of that period. That is above the Medical Instruments & Supplies industry median of 14.9× and above the Healthcare sector median of 8.4×.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 18.0× | (4.25%) |
| FY2024 | 18.8× | 27.04% |
| FY2023 | 14.8× | (36.47%) |
| FY2022 | 23.3× | 10.32% |
| FY2021 | 21.1× | (5.74%) |
| FY2020 | 22.4× | 14.73% |
| FY2019 | 19.5× | (53.26%) |
| FY2018 | 41.7× | (44.43%) |
| FY2017 | 75.1× | 301.25% |
| FY2016 | 18.7× | 17.26% |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Sep 2026 | 15.5× | (6.53%) |
| Jun 2026 | 16.6× | (1.15%) |
| Mar 2026 | 16.8× | (6.84%) |
| Dec 2025 | 18.0× | 27.23% |
| 43 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| PLSE Pulse Biosciences, Inc compare | n/m |
| MMED MiniMed Group, Inc. compare | n/m |
| NVST Envista Holdings Corporation compare | 10.3× |
| STVN Stevanato Group S.p.A. compare | 11.3× |
| MMSI Merit Medical Systems, Inc. compare | 15.5× |
| ICUI ICU Medical, Inc. | 16.0× |
| TFX Teleflex Incorporated compare | 35.7× |
| WRBY Warby Parker Inc. compare | 50.2× |
| ATRC AtriCure, Inc. compare | 83.7× |
| Medical Instruments & Supplies industry median | 14.9× |
| Healthcare sector median | 8.4× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on ICUI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement